News Astellas suffers pancreatic cancer failure with Vyloy Astellas' effort to expand the reach of its first-in-class claudin 18.2 drug Vyloy into pancreatic cancer has had a major setback.
News UCB drug for rare disease TK2d boosts survival UCB's experimental medicine for TK2d, currently under regulatory review, offers hope to patients with the devastating rare disease.
R&D Staying on course: How hybrid FSP/FSO models are shaping cli... Biotech and pharma companies increasingly require additional agility, flexibility, and operational efficiency in their clinical research operations.
News Sanofi, Orano cue up filings for GEP-NET radioligand therapy Clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings.
News MSD advances on a broad front with TL1A drug tulisokibart MSD's confidence in its anti-TL1A drug tulisokibart in inflammatory diseases is made apparent by a decision to start trials in three new indications.
News AZ chalks up another positive trial for hypertension drug AstraZeneca's baxdrostat has hit the mark in another phase 3 trial in resistant hypertension, keeping it on track for filing later this year.
News FDA follows experts' advice and blocks Capricor DMD therapy The FDA has dashed Capricor's hope of getting approval for its cell therapy for Duchenne muscular dystrophy, wreaking havoc with its share price.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.